Ginkgo Bioworks Holdings, Inc. 8-K

What Happened
On May 7, 2026, Ginkgo Bioworks Holdings, Inc. (ticker: DNA) filed a Form 8-K (Item 2.02) to report its results of operations and financial condition and furnished a press release announcing financial results for the quarter ended March 31, 2026. The press release is included as Exhibit 99.1 to the 8-K. The report is signed by Steven Coen, Chief Financial Officer.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition)
• Reporting period: Quarter ended March 31, 2026 (Q1 2026)
• Disclosure provided as a press release furnished as Exhibit 99.1 to the 8-K
• 8-K signed by Steven Coen, Chief Financial Officer

Why It Matters
This 8-K signals that Ginkgo has released its quarterly earnings and related financial information — essential for assessing recent revenue, earnings, cash position, and any company commentary or guidance. Retail investors should review the furnished press release (Exhibit 99.1) and any related filings (e.g., the upcoming 10‑Q) for the specific revenue, profit/loss, cash flow figures, and management commentary before making investment decisions.